BioCryst’s BCX7353 Prevents Attacks in HAE Patients, Phase 2 Trial Shows

Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein, reduces the rate of attacks in hereditary angioedema (HAE) patients by more than 70%, a Phase 2 study shows. Also, more patients receiving the prophylactic, or preventive, treatment remained without an attack during the study’s four-week duration. The study,…

European Agency Issues Positive Opinion on Orphan Drug Status for BXC7353 to Treat HAE

The European Medicines Agency issued a positive opinion on BioCryst Pharmaceuticals’ application for orphan drug status of BCX7353 to treat hereditary angioedema (HAE). The European Commission is expected to adopt the recommendation from the EMA’s Committee for Orphan Medicinal Products in the next 30 days. With orphan drug designation, BCX7353 will receive…